刘赟, 曹芳, 夏凡童, 闫杰, 赵强. 长链非编码RNA 00682通过调节MYCN表达促进神经母细胞瘤的增殖和转移能力[J]. 中国肿瘤临床, 2021, 48(22): 1151-1157. DOI: 10.12354/j.issn.1000-8179.2021.20211589
引用本文: 刘赟, 曹芳, 夏凡童, 闫杰, 赵强. 长链非编码RNA 00682通过调节MYCN表达促进神经母细胞瘤的增殖和转移能力[J]. 中国肿瘤临床, 2021, 48(22): 1151-1157. DOI: 10.12354/j.issn.1000-8179.2021.20211589
shu
Yun Liu, Fang Cao, Fantong Xia, Jie Yan, Qiang Zhao. Long noncoding RNA 00682 promotes proliferation and metastasis of neuroblastoma by regulating MYCN expression[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(22): 1151-1157. DOI: 10.12354/j.issn.1000-8179.2021.20211589
Citation: Yun Liu, Fang Cao, Fantong Xia, Jie Yan, Qiang Zhao. Long noncoding RNA 00682 promotes proliferation and metastasis of neuroblastoma by regulating MYCN expression[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(22): 1151-1157. DOI: 10.12354/j.issn.1000-8179.2021.20211589
shu

长链非编码RNA 00682通过调节MYCN表达促进神经母细胞瘤的增殖和转移能力

Long noncoding RNA 00682 promotes proliferation and metastasis of neuroblastoma by regulating MYCN expression

    摘要
  • 摘要:
      目的  研究神经母细胞瘤中长链非编码RNA 00682（LINC00682）的表达与MYCN表达量之间的关系，以及LINC00682调节神经母细胞瘤功能的机制。
      方法  收集2009年12月至2019年12月天津医科大学肿瘤医院104例不同分期的神经母细胞瘤临床标本及其病理及预后信息，通过实时荧光定量PCR检测LINC00682在临床标本和神经母细胞瘤细胞系的表达并分析其表达量与临床病理特征及预后的关系。在SK-N-Be2和SK-N-AS细胞系中应用小干扰RNA抑制LINC00682表达，进一步利用CCK-8和生长曲线检测其增殖能力，利用划痕实验和侵袭实验检测其转移能力，并在SK-N-Be2细胞系中检测MYCN的表达。
      结果  实时定量PCR检测104例神经母细胞瘤临床标本发现LINC00682在高危组的表达量明显高于低危组和中危组，分析临床信息得出LINC00682的表达与肿瘤转移、病理类型，临床分期和患者预后相关。在5种神经母细胞瘤细胞系中，LINC00682在MYCN扩增细胞系SK-N-Be2和IMR-32的表达水平显著高于非MYCN扩增细胞系SK-N-AS、SK-N-SH和SH-SY5Y。应用实时荧光定量PCR检测48例神经母细胞瘤临床标本中LINC00682和MYCN的表达，两者呈正相关。应用小干扰RNA抑制LINC00682在SK-N-Be2和SK-N-AS中的表达后，神经母细胞瘤细胞的增殖和转移能力明显下降，同时在SK-N-Be2细胞系MYCN的mRNA和蛋白水平均受到抑制。
      结论  LINC00682的高表达与神经母细胞瘤的肿瘤转移、病理类型，临床分期和预后相关，并且LINC00682可能通过影响MYCN的表达促进神经母细胞瘤细胞的增殖和转移。

     

    Abstract:
      Objective  To study the relationship between the expression of long noncoding RNA 00682 (LINC00682) and MYCN expression in neuroblastoma, and to study the function of LINC00682 in regulating neuroblastoma biological characteristics.
      Methods  A total of 104 cases clinical specimens of neuroblastoma and their corresponding pathological, prognostic information were collected from the Tianjin Medical University Cancer Institute & Hospital between December 2009 to December 2019. The expression of LINC00682 in these clinical specimens and neuroblastoma cell lines was detected with real-time quantitative PCR, and the relationship between its expression, clinicopathological information, and prognosis was analyzed. The expression of LINC00682 was inhibited by small interfering RNA in SK-N-Be2 and SK-N-AS cell lines. Further we detected its proliferation ability by CCK-8 and growth curve assays, detected its metastasis ability by wound healing and invasion assays. The expression of MYCN was detected in the SK-N-Be2 cell line.
      Results  The expression of LINC00682 in the high-risk group was significantly higher than that in low-risk and medium-risk groups. Clinically, the expression of LINC00682 was related to metastasis, pathological type, clinical stage, and prognosis. Among the five neuroblastoma cell lines, the expression level of LINC00682 in MYCN amplified cell lines SK-N-Be2 and IMR-32 was significantly higher than that in non MYCN amplified cell lines SK-N-AS, SK-N-SH, and SH-SY5Y. The expressions of LINC00682 and MYCN in 48 clinical specimens of neuroblastoma were detected by real-time quantitative PCR. High positive linear correlation was evident. Inhibition of LINC00682 expression in SK-N-Be2 and SK-N-AS cells inhibited the proliferation and metastasis of these neuroblastoma cells. Inhibition of LINC00682 in SK-N-Be2 cells also inhibited mRNA and protein production of MYCN.
      Conclusions  The high expression of LINC00682 is related to tumor metastasis, pathological type, clinical stage, and prognosis of neuroblastoma. LINC00682 could promote proliferation and metastasis of neuroblastoma by affecting the expression of MYCN.

     

    • HTML全文
    • 参考文献(25)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回